跳至主要内容
临床试验/NCT00882336
NCT00882336已完成不适用

Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice

AstraZeneca1 个研究点 分布在 1 个国家目标入组 7,200 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
7,200
试验地点
1
主要终点
LDL-cholesterol, systolic and diastolic blood pressure, Tot. cholesterol, Non-HDL cholesterol, HDL-cholesterol, waist and hip circumference, HbA1c

研究概览

简要总结

The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.

The patient's participation consists of a single study visit during a routine visit of the patient to the clinic/office.

Study variables will be measured:

  • By an interview between physician and patient during the visit and/or available medical records' information: social and demographic patient characteristics, relevant family medical history, current medication.
  • By questions asked to the physician: physician perception of patients' CV risk factor, guidelines adherence and cost-containment.
  • By measurement performed to the patient during the visit: weight, height, BMI, waist and hip circumference will be measured.
  • CV risk factors (blood parameters) will be measured by collecting available data documented within the last year in the medical records and by the collection and analyses of a blood sample during the visit.

研究设计

研究类型
Observational
时间视角
Cross Sectional

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provision of informed consent.
  • Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalisation for a CV event) from Primary Care or hospital outpatient clinic.

排除标准

  • Subjects who are unwilling or unable to provide informed consent
  • Previous CV disease event or hospitalisation for a CV event
  • Current participation in a clinical trial

结局指标

主要结局

LDL-cholesterol, systolic and diastolic blood pressure, Tot. cholesterol, Non-HDL cholesterol, HDL-cholesterol, waist and hip circumference, HbA1c

时间窗: Cross-sectional

Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history.

时间窗: Cross-sectional

次要结局

  • Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate.(Cross-sectional)
  • BMI, Score based 10 year CHD mortality > 5%, High Risk patients (no. and %)(Cross-sectional)
  • Use of concomitant medication: anticoagulant, anti hypertensive, antidiabetic, lipid-lowering drugs(Cross-sectional)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验